|
Acute chest pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
GDF-15 predicts cardiovascular events in acute chest pain patients.
|
28771550 |
2017 |
|
Acute Chest Syndrome
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The NPs and GDF-15 provide the strongest prognostic increment to cTn levels in ACS.
|
28315120 |
2017 |
|
Acute Chest Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
Methods We measured baseline GDF-15 (Roche, Elecsys) in 4330 patients with NSTE-ACS enrolled in MERLIN-TIMI 36.
|
30710475 |
2019 |
|
Acute Chest Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
The way GDF-15 patterns in post-ACS patients behave on the long term is largely unknown.
|
31047655 |
2019 |
|
Acute Chest Syndrome
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We measured the circulating concentrations of follistatin-like 1 (FSTL1) and GDF15 in 1369 patients with ACS.
|
22675198 |
2012 |
|
Acute Chest Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
In a pre-specified nested analysis within a randomized, double-blind trial of ezetimibe/simvastatin versus placebo/simvastatin (IMPROVE-IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]), high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, growth-differentiation factor-15, and high-sensitivity C-reactive protein was measured in 7,195 patients stabilized (1 month post-randomization) after ACS.
|
31439215 |
2019 |
|
Acute Chest Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the long-term prognostic value of GDF-15 in ACS.
|
31369736 |
2019 |
|
Acute Chest Syndrome
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
GDF-15 levels may therefore be useful as part of decision support concerning long-term antithrombotic treatment in patients post-ACS.
|
28411246 |
2017 |
|
Acute Chest Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
In conclusion, increased GDF-15 plasma concentrations at the time of PCI and stent implantation might classify high-risk patients with ACS who benefit from high-dose, highly efficient statins.
|
28734463 |
2017 |
|
Acute Chest Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
There was a significant association between high-level GDF-15 and mortality, recurrent MI in patients with ACS.
|
31029521 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
GDF-15 is as an independent marker of all-cause mortality and CV events in patients with coronary artery disease, and may help select patients with non-ST-elevation acute coronary syndrome for early revascularization and more intensive medical therapies.
|
28062617 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-term prognostic value of growth differentiation factor-15 in acute coronary syndromes.
|
31369736 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growth-differentiation factor-15 predicts adverse cardiac events in patients with acute coronary syndrome: A meta-analysis.
|
31029521 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Usefulness of Elevated Levels of Growth Differentiation Factor-15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High-Dose Statin Therapy.
|
28734463 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death.
|
30427997 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesize that geriatric conditions reflecting biological age might be stronger determinants of GDF-15 than chronological age in elderly patients with acute coronary syndrome.
|
31130280 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Temporal Pattern of Growth Differentiation Factor-15 Protein After Acute Coronary Syndrome (From the BIOMArCS Study).
|
31047655 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome.
|
22675198 |
2012 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
|
28411246 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
As well, GDF-15 was found a prognostic biomarker of heart failure and acute coronary syndrome.
|
21718220 |
2011 |
|
Acute heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
Seven circulating biomarkers [NT-proBNP, high sensitivity cardiac troponin T (hs-cTnT), soluble ST2 (sST2), growth differentiation factor 15 (GDF-15), cystatin-C, galectin-3, and high sensitivity C-reactive protein (hs-CRP)] were measured at baseline and on days 2, 5, 14, and 60 in 1161 patients enrolled in the RELAX-AHF trial.
|
28133908 |
2017 |
|
Acute heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to investigate the prognostic predictive value of growth differentiation factor-15 (GDF-15) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in assessing hospitalized patients with acute heart failure (AHF).
|
31567379 |
2019 |
|
Acute heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15.
|
30144302 |
2018 |
|
Acute hypercapnic respiratory failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, we evaluated the role of the biomarkers IL-8 and GDF-15 in predicting 28-day mortality in patients with AHRF who receive treatment with NPPV.
|
28178959 |
2017 |
|
Acute myocardial infarction
|
0.080 |
Biomarker
|
disease |
BEFREE |
Conclusion GDF-15 and TRAIL-R2 were the most powerful Proximity Extension Assay chip biomarkers in predicting long-term all-cause mortality in patients with acute myocardial infarction.
|
28762762 |
2017 |